Arcturus Therapeutics Holdings Inc (ARCT)
Stock chart
Earnings
Value bought
Past 90 days
Value sold
Past 90 days
Net insiders buying
Past 90 days
Trades (buy and sell)
Past 90 days
Search
| Notification date | Transaction date | B/S Transaction type | Insider and/or position |
Nb. shares Price Value |
Number of shares | Price | Value | Details |
|---|---|---|---|---|---|---|---|---|
| 2024-10-16 | 2024-10-15 | PS Planned sale |
Chief Scientific Officer & COO Officer |
12,000
-2.7%
20.76USD 249,121 |
12,000 -2.7% | 20.76 | USD 249,121 | |
| 2024-06-14 | 2024-06-12 | S Sale |
Chief Financial Officer Executive Director |
50,000
-18.5%
32.03USD 1,601,500 |
50,000 -18.5% | 32.03 | USD 1,601,500 | |
| 2024-06-07 | 2024-06-05 | PS Planned sale |
Chief Scientific Officer & COO Officer |
114
-0.0%
45.00USD 5,130 |
114 -0.0% | 45.00 | USD 5,130 | |
| 2024-06-04 | 2024-06-03 | PS Planned sale |
Chief Scientific Officer & COO Officer |
26,000
-5.5%
40.01USD 1,040,234 |
26,000 -5.5% | 40.01 | USD 1,040,234 | |
| 2024-03-27 | 2024-03-25 | PS Planned sale |
Chief Scientific Officer & COO Officer |
17,435
-3.6%
35.02USD 610,574 |
17,435 -3.6% | 35.02 | USD 610,574 | |
| 2024-03-21 | 2024-03-19 | PS Planned sale |
Chief Scientific Officer & COO Officer |
8,565
-1.7%
35.01USD 299,839 |
8,565 -1.7% | 35.01 | USD 299,839 | |
| 2023-11-03 | 2023-11-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-1.0%
18.72USD 93,602 |
5,000 -1.0% | 18.72 | USD 93,602 | |
| 2023-10-04 | 2023-10-02 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-1.0%
25.61USD 128,062 |
5,000 -1.0% | 25.61 | USD 128,062 | |
| 2023-09-05 | 2023-09-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-1.0%
31.45USD 157,264 |
5,000 -1.0% | 31.45 | USD 157,264 | |
| 2023-08-03 | 2023-08-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-1.0%
34.91USD 174,550 |
5,000 -1.0% | 34.91 | USD 174,550 | |
| 2023-07-18 | 2023-07-14 | PS Planned sale |
See Remarks Officer |
6,968
-88.0%
35.00USD 243,880 |
6,968 -88.0% | 35.00 | USD 243,880 | |
| 2023-07-18 | 2023-07-14 | PS Planned sale |
Chief Scientific Officer & COO Officer |
25,000
-4.6%
35.01USD 875,250 |
25,000 -4.6% | 35.01 | USD 875,250 | |
| 2023-07-07 | 2023-07-03 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-0.9%
28.75USD 143,750 |
5,000 -0.9% | 28.75 | USD 143,750 | |
| 2023-06-05 | 2023-06-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-0.9%
27.16USD 135,800 |
5,000 -0.9% | 27.16 | USD 135,800 | |
| 2023-05-12 | 2023-05-11 | PS Planned sale |
Chief Scientific Officer & COO Officer |
7,925
-1.4%
30.24USD 239,652 |
7,925 -1.4% | 30.24 | USD 239,652 | |
| 2023-05-12 | 2023-05-10 | PS Planned sale |
Chief Scientific Officer & COO Officer |
17,075
-2.9%
30.00USD 512,250 |
17,075 -2.9% | 30.00 | USD 512,250 | |
| 2023-05-03 | 2023-05-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-0.9%
25.93USD 129,650 |
5,000 -0.9% | 25.93 | USD 129,650 | |
| 2023-04-19 | 2023-04-18 | PS Planned sale |
See Remarks Officer |
6,968
-88.0%
28.18USD 196,358 |
6,968 -88.0% | 28.18 | USD 196,358 | |
| 2023-04-05 | 2023-04-03 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-0.8%
25.38USD 126,900 |
5,000 -0.8% | 25.38 | USD 126,900 | |
| 2023-03-08 | 2023-03-06 | PS Planned sale |
Chief Scientific Officer & COO Officer |
5,000
-0.8%
16.07USD 80,350 |
5,000 -0.8% | 16.07 | USD 80,350 | |
| 2022-12-19 | 2022-12-15 | B Purchase | Non-Executive Director |
2,222
+9.8%
18.00USD 39,996 |
2,222 +9.8% | 18.00 | USD 39,996 | |
| 2022-11-28 | 2022-11-23 | B Purchase |
President and CEO Executive Director |
5,000
+0.3%
16.51USD 82,550 |
5,000 +0.3% | 16.51 | USD 82,550 | |
| 2022-01-06 | 2022-01-04 | PS Planned sale |
Chief Scientific Officer & COO Officer |
8,100
-1.3%
40.00USD 324,000 |
8,100 -1.3% | 40.00 | USD 324,000 | |
| 2021-12-20 | 2021-12-16 | PS Planned sale |
Chief Scientific Officer & COO Officer |
3,633
-0.6%
40.00USD 145,328 |
3,633 -0.6% | 40.00 | USD 145,328 | |
| 2021-12-10 | 2021-12-08 | PS Planned sale |
Chief Scientific Officer & COO Officer |
6,367
-1.0%
40.00USD 254,680 |
6,367 -1.0% | 40.00 | USD 254,680 | |
| 2021-11-03 | 2021-11-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.6%
44.41USD 444,100 |
10,000 -1.6% | 44.41 | USD 444,100 | |
| 2021-10-04 | 2021-10-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.6%
44.36USD 443,600 |
10,000 -1.6% | 44.36 | USD 443,600 | |
| 2021-04-05 | 2021-04-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.5%
42.95USD 429,500 |
10,000 -1.5% | 42.95 | USD 429,500 | |
| 2021-03-03 | 2021-03-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.5%
54.23USD 542,300 |
10,000 -1.5% | 54.23 | USD 542,300 | |
| 2021-02-03 | 2021-02-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.5%
75.31USD 753,100 |
10,000 -1.5% | 75.31 | USD 753,100 | |
| 2021-01-05 | 2021-01-04 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.4%
46.40USD 464,000 |
10,000 -1.4% | 46.40 | USD 464,000 | |
| 2020-12-10 | 2020-12-09 | S Sale |
Ultragenyx Pharmaceutical Inc. Non-Executive Director Large shareholder |
357,745
-14.0%
94.97USD 33,975,043 |
357,745 -14.0% | 94.97 | USD 33,975,043 | |
| 2020-12-10 | 2020-12-08 | S Sale |
Ultragenyx Pharmaceutical Inc. Non-Executive Director Large shareholder |
442,255
-14.7%
105.54USD 46,675,593 |
442,255 -14.7% | 105.54 | USD 46,675,593 | |
| 2020-12-03 | 2020-12-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.4%
96.19USD 961,900 |
10,000 -1.4% | 96.19 | USD 961,900 | |
| 2020-11-03 | 2020-11-02 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.4%
55.28USD 552,800 |
10,000 -1.4% | 55.28 | USD 552,800 | |
| 2020-10-02 | 2020-10-01 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.4%
42.83USD 428,300 |
10,000 -1.4% | 42.83 | USD 428,300 | |
| 2020-09-04 | 2020-09-03 | PS Planned sale |
Chief Scientific Officer & COO Officer |
10,000
-1.4%
45.16USD 451,600 |
10,000 -1.4% | 45.16 | USD 451,600 | |
| 2020-06-12 | 2020-06-12 | B Purchase |
See Remarks Officer |
450
+90.0%
33.33USD 14,999 |
450 +90.0% | 33.33 | USD 14,999 | |
| 2020-06-10 | 2020-06-10 | B Purchase |
President and CEO Executive Director |
1,000
+0.1%
31.69USD 31,690 |
1,000 +0.1% | 31.69 | USD 31,690 | |
| 2020-06-10 | 2020-06-10 | B Purchase |
Chief Financial Officer Executive Director |
5,000
+1.9%
29.74USD 148,700 |
5,000 +1.9% | 29.74 | USD 148,700 | |
| 2019-12-09 | 2019-12-05 | B Purchase |
SASSINE ANDY Chief Financial Officer Executive Director |
5,649
+2.2%
9.73USD 54,965 |
5,649 +2.2% | 9.73 | USD 54,965 | |
| 2019-12-05 | 2019-12-03 | B Purchase |
SASSINE ANDY Chief Financial Officer Executive Director |
10,000
+4.0%
10.00USD 100,000 |
10,000 +4.0% | 10.00 | USD 100,000 | |
| 2019-09-17 | 2019-09-13 | B Purchase |
2,300
+11.3%
10.58USD 24,334 |
2,300 +11.3% | 10.58 | USD 24,334 | ||
| 2019-09-12 | 2019-09-12 | B Purchase |
See Remarks |
500
+inf%
10.69USD 5,347 |
500 +inf% | 10.69 | USD 5,347 | |
| 2019-08-30 | 2019-08-29 | B Purchase |
Payne Joseph E President and CEO Executive Director Large shareholder |
5,000
+0.3%
11.22USD 56,100 |
5,000 +0.3% | 11.22 | USD 56,100 | |
| 2019-08-26 | 2019-08-23 | B Purchase |
SASSINE ANDY Chief Financial Officer Officer |
10,000
+4.2%
10.90USD 109,000 |
10,000 +4.2% | 10.90 | USD 109,000 | |
| 2019-08-21 | 2019-08-20 | B Purchase |
FARRELL PETER C Non-Executive Director |
4,432
+11.5%
10.85USD 48,087 |
4,432 +11.5% | 10.85 | USD 48,087 | |
| 2019-08-21 | 2019-08-19 | B Purchase |
FARRELL PETER C Non-Executive Director |
4,681
+13.8%
11.02USD 51,585 |
4,681 +13.8% | 11.02 | USD 51,585 |